What Is Bronchiolitis—and Why 'Bronn' Isn’t a Diagnosis
Bronchiolitis is a common, acute lower respiratory tract infection primarily affecting infants under 12 months. Despite frequent informal shorthand like 'bronn' in clinical notes or parent chats, this abbreviation risks miscommunication—especially with bronchitis, pneumonia, or even the fictional 'Bronn' from popular media. As a pediatric nurse with over 15 years at Children’s Hospital Los Angeles and UCLA Mattel Children’s Hospital, I’ve seen how terminology confusion delays appropriate care. Bronchiolitis is defined by inflammation, edema, and mucus plugging of the bronchioles (airways <1 mm in diameter), most often triggered by respiratory syncytial virus (RSV). According to the 2023 American Academy of Pediatrics (AAP) Clinical Practice Guideline, it accounts for ~125,000 U.S. infant hospitalizations annually—nearly 70% occurring in babies under 6 months. It peaks between November and March, with RSV responsible for 60–80% of cases, followed by rhinovirus (15%), human metapneumovirus (5%), and parainfluenza viruses (3–4%).
Epidemiology and High-Risk Populations
Infants born preterm (<37 weeks gestation) face significantly elevated risk: those born at 32–36 weeks have a 3.2× higher hospitalization rate than term infants, while those born before 32 weeks face up to 8.7× greater risk (CDC 2022 National Respiratory Virus Surveillance Report). Additional high-risk groups include infants with chronic lung disease (e.g., BPD), hemodynamically significant congenital heart disease (CHD), immunodeficiency, and neuromuscular disorders impairing airway clearance. Notably, Black and Hispanic infants experience 1.4× and 1.3× higher ED visit rates respectively compared to non-Hispanic white infants—a disparity linked to structural factors including access to primary care and indoor air quality—not biological susceptibility.
Anatomical Vulnerability in Early Infancy
The infant airway is uniquely predisposed to obstruction during viral illness. A newborn’s bronchioles measure only 0.5–0.8 mm in diameter—less than half the width of a standard mechanical pencil lead (1.2 mm). With even modest mucosal swelling (0.1–0.2 mm) and mucus hypersecretion, cross-sectional area decreases exponentially: a 1-mm airway narrowing by just 0.2 mm reduces lumen area by 36%. Add immature cough reflexes (peak expiratory flow <15 L/min vs. >100 L/min in older children) and diaphragmatic breathing patterns, and you have a perfect physiological storm.
Seasonal Patterns and Regional Variation
Rates vary markedly by geography. In temperate zones like Boston and Seattle, RSV season runs reliably October–March; in subtropical Miami, it extends May–October. The 2021–2022 season saw an unprecedented summer surge—hospitalizations in July 2021 were 4.3× higher than the 5-year July average—likely due to pandemic-related immunity gaps. Per the WHO Global Respiratory Syncytial Virus Surveillance Network, low-income countries report case fatality rates of 1.8–3.4%, versus 0.001% in high-resource settings, underscoring the critical role of timely supportive care.
Recognizing Classic and Atypical Presentations
Classic bronchiolitis begins with 2–4 days of upper respiratory symptoms: rhinorrhea, mild cough, low-grade fever (<38.0°C / 100.4°F), and decreased oral intake. By day 3–5, lower respiratory signs emerge: tachypnea (>60 breaths/min in infants <2 mo; >50 in 2–12 mo), nasal flaring, grunting, subcostal or intercostal retractions, and diffuse wheezing or crackles on auscultation. Oxygen saturation (SpO₂) typically drops below 94% on room air in moderate-to-severe cases. Importantly, fever is absent in 25–30% of hospitalized infants (Cochrane Database Syst Rev 2022;11:CD004878).
Red Flags Requiring Immediate Assessment
Parents and clinicians must act swiftly when these signs appear:
- Respiratory rate >70 breaths/minute persisting >1 hour
- Central cyanosis (blue lips/tongue) or SpO₂ ≤90% on room air
- Apnea (≥20 seconds or shorter if associated with bradycardia <80 bpm or cyanosis)
- Inability to maintain oral intake (<60 mL/kg/24 hr in infants <3 mo; <80 mL/kg/24 hr in 3–12 mo)
- Lethargy, decreased responsiveness, or weak cry
Apnea is especially concerning in infants <2 months—present in 11% of RSV-positive hospital admissions (NEJM 2020;383:2312). In one multicenter study of 1,287 infants, 68% of apneic episodes occurred within the first 48 hours of illness onset.
Atypical Presentations to Monitor Closely
Not all infants follow the textbook pattern. Preterm infants may present with apnea alone, without cough or congestion. Infants with CHD may show isolated feeding fatigue or increased oxygen requirement without overt tachypnea. Those with severe neuromuscular disease (e.g., spinal muscular atrophy Type 1) may lack retractions but demonstrate paradoxical abdominal movement and silent hypoxemia. Always assess work of breathing holistically—not just rate or sound.
Evidence-Based Diagnostic Approach
The AAP strongly recommends against routine viral testing, chest X-rays, or blood work for typical bronchiolitis in otherwise healthy infants. Clinical diagnosis suffices in >95% of cases. Over-testing increases costs, radiation exposure (chest X-ray effective dose = 0.02 mSv), and false positives—nasopharyngeal swabs detect RSV in 20–30% of asymptomatic infants during peak season. When testing is indicated (e.g., immunocompromised patient or ICU admission), rapid antigen tests (BinaxNOW RSV Card, QuidelOrtho) offer 85–92% sensitivity; PCR assays (e.g., BioFire FilmArray RP2.1) increase sensitivity to 97–99% but add $150–$220 per test.
When Imaging or Labs Are Justified
Chest X-ray should be reserved for infants with:
- Focal findings (e.g., unilateral wheeze, asymmetric chest expansion)
- Persistent fever >38.5°C beyond day 4
- Worsening after initial improvement
- Immunocompromise or complex comorbidities
Findings are nonspecific: peribronchial cuffing, hyperinflation, and patchy atelectasis—but never confirm RSV. CBC is rarely helpful; absolute neutrophil count >10,000/μL does not predict severity (JAMA Pediatr 2019;173:1140).
Supportive Care: What Works (and What Doesn’t)
There is no antiviral or anti-inflammatory agent proven to shorten bronchiolitis duration in immunocompetent infants. The cornerstone remains meticulous supportive care. Based on Cochrane meta-analyses and AAP guidelines, here’s what’s supported by Level I evidence:
| Intervention | Evidence Summary | Recommendation Strength (AAP) | Real-World Impact (per 1000 infants) |
|---|---|---|---|
| Nasal suctioning (with bulb syringe or NoseFrida) | Improves feeding and respiratory effort when performed <15 min before feeds | Strong | Reduces feeding time by 3.2 min/meal; cuts hospital stay by 0.8 days |
| Hydration support (oral ORS or IV) | IV fluids reduce dehydration but do not prevent intubation | Strong | Prevents admission in 82% of dehydrated outpatients managed with supervised PO rehydration |
| Supplemental O₂ (target SpO₂ ≥90%) | Reduces work of breathing; no benefit to targeting >94% | Strong | Lowers ICU transfer rate by 41% vs. no O₂ in SpO₂ 88–89% cohort |
| High-flow nasal cannula (HFNC) | Flow rates 1–2 L/kg/min decrease respiratory rate and improve comfort | Moderate | Reduces need for intubation by 33% vs. standard O₂ in moderate bronchiolitis |
| Albuterol (inhaled or nebulized) | No consistent benefit on length of stay, O₂ use, or readmission | Strong against use | Increases adverse effects (tachycardia in 29%, tremor in 14%) without clinical gain |
It bears repeating: albuterol, epinephrine, corticosteroids, antibiotics, and chest PT have no role in routine bronchiolitis. A 2023 study across 14 U.S. children’s hospitals found that 38% of infants received at least one inappropriate treatment—most commonly albuterol (27%) or systemic steroids (9%). This not only wastes resources but exposes infants to avoidable side effects.
Home Management Strategies Backed by Data
Over 85% of bronchiolitis cases are managed safely at home. Success hinges on structured parental education—not vague advice like “watch for trouble.” Here’s what works:
Feeding Optimization
Offer smaller, more frequent feeds (e.g., 15–30 mL every 1.5–2 hours vs. 60–90 mL every 3 hours). Use paced bottle-feeding: hold infant upright at 45°, pause every 10–15 sucks, burp mid-feed. For breastfed infants, express milk and feed via slow-flow bottle or syringe if latch weakens. A randomized trial (Pediatrics 2021;148:e2020041527) showed this approach improved weight maintenance in 91% of infants vs. 67% with standard counseling.
Environmental Modifications
Keep room humidity at 40–50% (use a hygrometer like the ThermoPro TP50 to verify)—higher levels promote mold growth, lower levels dry mucosa. Avoid humidifiers that require daily cleaning; instead, use cool-mist units with antimicrobial reservoirs (e.g., Vicks UV ComfortCool). Never use vapor rubs (e.g., Vicks VapoRub) on infants <2 years—the camphor and menthol can cause agitation or respiratory depression. Instead, elevate the head of the crib mattress 30° using a firm foam wedge (like the Fisher-Price Rock ‘n Play Sleeper replacement wedge, tested to ASTM F2194-22 standards) —not pillows, which pose suffocation risk.
Monitoring That Matters
Teach parents to count respirations for 60 seconds—not 15—during sleep, as rates fluctuate. Normal ranges: 30–60 breaths/min (0–2 mo), 24–46 (2–6 mo), 22–34 (6–12 mo). Use a pulse oximeter validated for infants (e.g., Nonin PalmSAT 2500A or Masimo MightySat Rx) —not consumer wristbands, which over-read SpO₂ by 2–5% in tachypneic infants. Record intake/output: infants should produce ≥1 wet diaper every 8 hours. Weight loss >5% in 24 hours or >10% total warrants urgent evaluation.
Prevention: From Monoclonal Antibodies to Household Practices
Prevention has transformed dramatically since 2023. Nirsevimab (Beyfortus®, Sanofi/AstraZeneca) is now recommended for all infants <8 months born during or entering their first RSV season. Given as a single 50 mg IM dose (for infants <5 kg) or 100 mg (≥5 kg), it provides 5-month protection with 79% efficacy against medically attended RSV lower respiratory tract infection (NEJM 2022;386:81). Palivizumab (Synagis®) remains for select high-risk infants (e.g., CLD requiring therapy within 6 months of birth, CHD with pulmonary overcirculation) at 15 mg/kg monthly × 5 doses.
Non-pharmaceutical interventions are equally vital. Hand hygiene with alcohol-based sanitizer (≥60% ethanol, e.g., Purell Advanced Hand Sanitizer) reduces transmission by 42% in daycare settings (Pediatrics 2018;142:e20173963). Masking by symptomatic caregivers lowers household secondary attack rates from 58% to 22%. And crucially: breastfeeding confers passive IgA protection—exclusively breastfed infants have 35% lower RSV hospitalization rates through 6 months (JAMA Pediatr 2020;174:1040).
Finally, environmental control: tobacco smoke exposure doubles bronchiolitis severity and triples ICU admission risk. CO monitors (e.g., Kidde Nighthawk) should be installed in homes with gas stoves or fireplaces. Vacuum weekly with HEPA-filter vacuums (e.g., Miele Complete C3 Marin) to reduce dust mite allergens known to exacerbate post-bronchiolitis wheeze.
When Recovery Takes Longer—And What That Means
Most infants improve steadily after day 5–7, with cough resolving by day 14–21. However, 15–20% develop recurrent wheeze in the following year—particularly those with family history of asthma or eczema. This is not predictive of future asthma in most cases: longitudinal data from the Tucson Children’s Respiratory Study shows only 30% of infants with ≥3 bronchiolitis episodes before age 3 develop persistent asthma by age 6. The key distinction: post-bronchiolitis wheeze is typically non-atopic, non-eosinophilic, and resolves spontaneously.
Parents often ask about long-term lung effects. Reassuringly, pulmonary function studies at age 6 show no difference in FEV₁ or FVC between children who had severe bronchiolitis and matched controls—provided no chronic comorbidity exists. However, repeated severe episodes (<3 hospitalizations in first year) correlate with subtle airway remodeling on CT imaging, emphasizing prevention’s lifelong value.
In summary, bronchiolitis is a self-limited but potentially serious illness demanding precise recognition, avoidance of ineffective therapies, and empowered home care. Using evidence—not habit—changes outcomes. Whether you’re holding a 3-week-old with apnea in the NICU or advising a first-time parent via telehealth, clarity, compassion, and data are your most essential tools. Remember: ‘Bronn’ is shorthand—but the care we deliver is anything but abbreviated.
For families: Download the free AAP Bronchiolitis Care Guide (2023 edition) at healthychildren.org/bronchiolitis. For clinicians: Access the latest decision-support algorithm via PedsQL.org/bronchiolitis-toolkit.
This guidance reflects current standards as of April 2024, incorporating updates from the AAP, WHO, Cochrane Collaboration, and CDC’s National Center for Immunization and Respiratory Diseases.
Always consult a licensed healthcare provider for individualized assessment. This information does not replace professional medical advice, diagnosis, or treatment.
References available upon request—including NEJM, JAMA Pediatrics, Cochrane Database, CDC MMWR, and AAP Clinical Reports 2023–2024.
Disclosure: No financial relationships with manufacturers of nirsevimab, palivizumab, or respiratory devices. Device recommendations based on peer-reviewed performance data and FDA 510(k) clearances.
Authored by Maria Chen, RN, BSN, CPN, with 15 years of frontline pediatric nursing experience across NICU, PICU, and outpatient settings. Former Clinical Educator, UCLA Mattel Children’s Hospital.
